Biotec Pharmacon ASA is a biotechnology company developing, producing and marketing immune modulating beta-glucans and novel recombinant enzymes. The Company is organized into two business areas, each managed as a separate operating unit.
For more information about Biotec Pharmacon go to biotec.no
Biotec BetaGlucans is a subsidiary of Biotec Pharmacon and focus on the use of immunomodulatory beta-1,3/1,6-glucan derivered from yeast in different application areas: including wound care, cancer adjuvant, animal health and human nutrition.
Soluble BetaGlucans management
Rolf (born 1959) holds a M.Sc. in biology and a Ph.D in biochemistry from the University of Tromsø, where he was employed as researcher from 1988 to 1998.
Finn KetlerVice President, Wound Care
Finn (born 1962) has a M.Sc. degree from Aarhus Business School. Finn has a long and extensive background within medical devices and wound care.
Ingrid SkjævelandScientific Product manager Woulgan
Ingrid (born 1977) holds a Civil Engineer in Biotechnology and a PhD in Immunology from the University of Tromsø.
Hubertus RuthmanCommercial Manager Germany
Hubertus holds a Master of Business Administration and has many years of experience in national and international marketing and sales roles in the medical device area.